Company / Operating Cash Flow
Valion Bio, Inc. Operating Cash Flow History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$8.5M
FY2024
5-year range
-$8.9M / -$5.6M
FY2022-FY2024
Trend
+4.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$6M to -$9M over the past 2 years.
Based on SEC 10-K filings.
-$9M in FY2024.
Declined from -$6M to -$9M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow increased 4.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$8.5M | +4.6% |
| FY2023 | -$8.9M | -58.9% |
| FY2022 | -$5.6M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026